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The death toll of seasonal inﬂuenza in Hong Kong in 2017 has hit the
headlines and received broad media coverage worldwide. Some
commentators compared it with that of severe acute respiratory
syndrome (SARS) during the outbreak in 2003. What was it really
like? As of 26 August 2017, the inﬂuenza activity in Hong Kong had
further declined from the peak and returned to the baseline, indicating
that the 2016–2017 inﬂuenza season is over. From 5 May to 26
August, 586 severe seasonal inﬂuenza cases were recorded, including
19 pediatric cases (aged below 18). Among them, 429 adults and 3
children had died. Hospitalization rates were high, especially for the
elderly (aged ⩾ 65). H3N2 was the predominating subtype detected.
It is known that H3N2 is more virulent than other subtypes such as
H1N1,1 causing more severe infection and higher death rate. It
remains to be validated whether the predominant H3N2 viruses in
this season have undergone antigenic drifts that reduce vaccine
effectiveness, as seen in the 2014–2015 season. It is noteworthy that
more than 35% of the H3N2 viruses found in May 2017 in Hong
Kong contain N121K mutation in the hemagglutinin (HA) protein,
which could render the vaccine less effective.2 To what extent this
might have exacerbated the severity of this inﬂuenza season in Hong
Kong merits further investigations. Since 45.4% of the fatal cases are
known to have received the inﬂuenza vaccine for the 2016–2017
season, the possibility that vaccination cannot effectively protect
infection with the circulating H3N2 viruses cannot be excluded.
How does this season compare to the previous ones? The most
recent H3N2 season was 2014–2015, whereas H1N1 predominated in
2013–2014 and 2015–2016. Whereas seasonal inﬂuenza activity peaked
in February and March in the previous three seasons, with an
exceptional second wave seen in June 2015, it plateaued in July
2017. Consistent with the notion that H3N2 is more virulent, there
were more severe cases and deaths in 2014–2015 than in 2013–2014 or
2015–2016. In contrast, the numbers of severe and death cases in the
peak week were similar for 2014–2015 and 2016–2017. The 2016–2017
season is drawing to a close at the end of August; the total number of
severe and death cases does not exceed that of 2014–2015 (Table 1).
The case fatality was about 2% in both seasons.
The above statistics indicates that the 2016–2017 inﬂuenza season in
Hong Kong is not more severe than any previous H3N2 season, such
as the one in 2014–2015. This was further corroborated by tabulation
of the numbers of severe cases by age groups, which indicated a similar
pattern for the 2014–2015 and 2016–2017 seasons, in which people
aged 50–64 and ⩾ 65 were most severely affected (Table 1). Underlying
diseases and immunosuppression are common in the severe cases in
these age groups. The pattern was not seen for the two H1N1 seasons
in 2013–2014 and 2015–2016.
Furthermore, the rates for inﬂuenza-associated hospitalization,
severe cases and deaths in the 2016–2017 season in Hong Kong were
generally within the boundaries expected for a H3N2 season and
comparable to those in other countries and regions in this and
previous H3N2 seasons. The disease burden of seasonal inﬂuenza is
substantial. As estimated by the Centers for Disease Control and
Prevention (CDC), there might have been 9.2–35.6 million cases of
inﬂuenza-related illnesses, 140 000–710 000 hospitalizations and
12 000–56 000 deaths annually in the United States since 2010. For
example, in the H3N2-dominant 2003–2004 season, the estimated
number of inﬂuenza-associated deaths with underlying respiratory and
circulatory causes in the United States was 48 614.3 The advanced
inﬂuenza surveillance system in Hong Kong has just provided a real-
life example in support of the estimation made by the CDC.
The Center for Health Protection of Hong Kong has done a superb
job in providing near real-time monitoring of seasonal inﬂuenza
activity in the territory. Starting from the 2014–2015 season, they went
one step further to announce their ﬁndings, including the numbers of
severe seasonal inﬂuenza cases and deaths to the general public. This
real-time weekly update of inﬂuenza activity helps to increase the
awareness and vigilance of people against the risk. However, it has also
triggered extensive media coverage, including exaggerated description
and unfair comparison, which cause panic, anxiety and overreaction
from residents, visitors and people from other regions.
Inﬂuenza-associated excess deaths with underlying diseases are
difﬁcult to track and might not be detected timely by the inﬂuenza
surveillance system in adjacent regions. Hence, a comparison of
numbers between different regions cannot reﬂect the severity of
seasonal inﬂuenza activity. Human infection of avian H5N1 and
H7N9 viruses has a case fatality of 60% and 40%, respectively.
Likewise, about of 10% of cases with SARS and 30% of cases with
Middle East respiratory syndrome are fatal. These are emerging viral
pathogens with unusual properties. If seasonal inﬂuenza is a known
evil, they are unknown beasts. Direct comparison of the numbers of
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deaths caused by seasonal inﬂuenza and these emerging viruses is
therefore misleading.
Increasing the transparency of inﬂuenza surveillance and sharing
more information about seasonal inﬂuenza activity with the public
should not be discouraged. In other words, not to announce is not an
option, but the question is how to explain to all stakeholders and
educate them about seasonal inﬂuenza, emerging microbes and
infections. There is much room for improvement in this aspect.
The numbers of severe inﬂuenza cases and deaths in the 2016–2017
season in Hong Kong remind us of the signiﬁcant morbidity and
mortality caused by seasonal inﬂuenza. Reducing the disease burden
and the impact on public hospitals in Hong Kong is our next
challenge. The percentage of people in the high-risk groups, including
children, the elderly and health professionals, in Hong Kong who
receive inﬂuenza vaccination is relatively low. Providing more
incentives, including more attractive subsidizing schemes, to these
groups might be helpful. Prescribing Tamiﬂu to the elderly who are at
higher risk has also been shown to be a safe and effective prophylactic
measure. Earlier concerns about the possibility that exposing more
people to Tamiﬂu might accelerate the development of drug resistance
can be relieved.4 Nevertheless, seasonal inﬂuenza will still keep us busy
in the years to come. New types of vaccines and antivirals are required
in our battle against inﬂuenza viruses.
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Table 1 The number of severe inﬂuenza cases in recent seasons in Hong Kong
Inﬂuenza season
(number of weeks under study)
Predominant
subtype
Number of severe cases
in the peak week
Number of severe cases in the season by age




0 –17 18–49 50–64 65 or above Total
2013−2014 (17) A/H1N1 32 23 54 73 139 289 22 138
2014−2015 (17) A/H3N2 74 18 21 65 561 665 56 447
2015−2016 (17) A/H1N1 44 27 58 133 218 436 18 157
2016−2017 (17) A/H3N2 75 19 27 89 451 586 56 300
Number of deaths includes deaths in public hospitals only. Original data: http://www.chp.gov.hk/ﬁles/xls/ﬂux_data.xlsx.
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